{"acquisitions":[],"changes":[],"country":"SE","description":"Asgard Therapeutics is a Swedish biotech developing direct cell reprogramming gene therapies, with lead candidate AT-108 turning tumor cells into antigen-presenting dendritic cells. The off-the-shelf therapy targets patients with solid tumors needing personalized anti-tumor immune responses. Science-published proof-of-concept data shows.","domain":"asgardtx.com","employees":null,"founded":2018,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":55.70293,"lng":13.192945,"location":"Lund","multiples":[],"name":"Asgard Therapeutics","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":32400000,"connectionsAmong":[],"currency":"EUR","date":"2024-03-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"asgardtx-com-2024-03-01-series-a","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-06","status":"attributed","url":null},"status":"attributed","type":"series-a","url":null}],"slug":"asgardtx-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-06","status":"attributed","url":null},{"fact":"existence","publisher":"asgardtx.com","retrievedAt":"2026-05-06","status":"self-reported","url":"https://asgardtx.com"},{"fact":"description","publisher":"asgardtx.com","retrievedAt":"2026-05-06","status":"self-reported","url":"https://asgardtx.com"}],"stage":"series-a","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":[],"totalRaisedUsd":32400000,"traction":[],"updatedAt":"2026-05-06","valuations":[]}